Physician profile
James Richardson
NPI 1306827266
$4,859.22
in general payments reported to CMS, 2019-2025
14 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $274 · 2021: $625 · 2022: $713 · 2023: $737 · 2024: $1,094 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,920.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,656.46 | 2021-2025 | Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $901.04 | 2019-2025 | Pifeltro, Zerbaxa, Dificid |
| Abbvie INC. | $584.16 | 2021-2025 | |
| Gilead Sciences, INC. | $476.77 | 2020-2025 | Biktarvy |
| Astellas Pharma US INC | $398.44 | 2019-2023 | Cresemba |
| Allergan, INC. | $259.84 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $136.17 | 2019-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $126.00 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Insmed, INC. | $112.83 | 2024-2025 | Arikayce |
| Ferring Pharmaceuticals INC. | $58.52 | 2022-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $51.09 | 2023 | Livtencity |
| Theratechnologies INC. | $47.96 | 2021-2022 | |
| Shionogi INC | $33.58 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $16.36 | 2024 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.